The Lupin CEO's infectious enthusiasm has taken the third-largest Indian drug company to a new level. Today, it is the only Asian company to figure in the list of top 10 largest and fastest-growing companies (by prescriptions) in the US, according to IMS Health, which tracks drug sales globally.
The eldest of Lupin founder and Chairman D.B. Gupta's five children, she graduated in pharmacy from the University of Mumbai, and later earned her MBA degree from J.L. Kellogg Graduate School of Management. After almost a decade as Lupin's global business head for US-Europe and other western markets, and as the mergers and acquisition head, Vinita, 47, has an impressive scorecard.
Vinita travels a lot to monitor the pharmaceuticals markets across Europe, Latin America, Africa and West Asia, and is aggressive with her direct marketing initiatives and brand acquisitions.
This year alone, Lupin has acquired five companies in South Africa, Russia, the US, Germany and Brazil. The acquisition of Gavis in the US for $880 million in July will be a big boost for the company's future. "Gavis has some 66 products pending for approval and another 65 products under development," says Vinita, adding that the acquisition helped Lupin to have its first manufacturing facility in the US.
Under Vinita's leadership, Lupin has acquired specialty products of Temmler Pharma in Germany, and Goanna brand premium therapeutic oils, rubs and ointments in Australia. Besides, she has played an important role in globalising Lupin, with a dozen acquisitions in the past decade to create marketing front ends in various geographies such as Pharma Dynamics in South Africa, Multicare Pharma in Philippines, Nanomi in Netherlands, Grin SA De CV in Mexico, Medquimica in Brazil and Biocom in Russia.
Lupin's anti-infective Suprax (cefixime), which commands a market size of $100 million, for example, is one of the fastest growing products in the US drug market. It also marked Lupin's entry into the US market for branded finished products and created a specialty pediatric sales force under the US subsidiary Lupin Pharmaceuticals Inc. In 2009, Lupin acquired the US rights for Antara, the cholesterol-lowering medication from Oscient Pharmaceuticals, which was facing bankruptcy, for Rs 185 crore. Today, different versions of Antara generate over $60 million to $65 million annually, despite generic competition in recent months from companies such as Mylan.
"Gavis acquisition offers complementary synergies (first US manufacturing plant, controlled substances and derma capabilities) and the business expects to contribute $300 million to Lupin's US revenues by 2017/18," say Edelweiss analysts Anshuman Gupta and Rahul Solanki.
"I know Vinita since I joined the strategic advisory board of Lupin. I have been impressed by her strategic capabilities and the clarity of vision. I was similarly impressed by her executional capabilities, which turned into fast and effective execution of the decisions taken.More than that, she is people and team oriented, and creates an inclusive environment, where people are heard and are involved in setting the strategy and effectively implementing it," says Francesco Granata, Senior Advisor at Warburg Pincus.
The company is also transforming from a predominantly generic company to a branded generics, specialty and complex generics-focused company. The target is to become a $5 billion turnover company by 2018. "Lupin has the capability to launch 100-120 products in the US over the next three years. Its aspirational target of $3.75 billion to $4 billion in organic revenues for FY18 is achievable," say Ambit analysts Aditya Khemka and Paresh Dave. And, Vinita is confident of achieving the target.
Copyright©2021 Living Media India Limited. For reprint rights: Syndications Today